Summit Therapeutics Inc

NASDAQ:SMMT   12:56:04 PM EDT
4.33
+0.05 (+1.17%)
Earnings Announcements

Summit Therapeutics Reports Q3 LOSS PER SHARE Of $0.26

Published: 11/16/2020 23:14 GMT
Summit Therapeutics plc (SMMT) - Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020.
Summit Therapeutics Inc Qtrly Loss per Share $0.26.
Summit Therapeutics Inc - Cash and Cash Equivalents on September 30, 2020, of $21.3 Million.
Revenue is expected to be $3.95 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $4.4 Million
Next Quarter EPS Guidance is expected to be -$0.22

More details on our Analysts Page.